试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-23
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
编号:NCT04892043登记状态:提前终止企业 / 申办者:SQZ Biotechnologies
药物 / 成分:SQZ-AAC-HPV、Ipilimumab、Nivolumab
登记的停止原因(原文):Corporate Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-23
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer
编号:NCT04927481登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:Mitoxantrone Hydrochloride Liposome Injection
登记的停止原因(原文):The sponsor has adjusted its R\&D strategy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-23
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
编号:NCT05345938登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:Mitoxantrone Hydrochloride Liposome
登记的停止原因(原文):Adjust the research strategy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-23
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
编号:NCT05357898登记状态:提前终止企业 / 申办者:SQZ Biotechnologies
药物 / 成分:SQZ-eAPC-HPV、Pembrolizumab
登记的停止原因(原文):Corporate Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-22
Serratus Plane Block for Postoperative Pain Control
编号:NCT02865928登记状态:提前终止企业 / 申办者:Northwell Health
药物 / 成分:Bupivicaine HCl、Normal Saline
登记的停止原因(原文):We decided to terminate this study due to staffing changes and other limitations posed by the COVID-19 pandemic.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-22
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
编号:NCT03357224登记状态:提前终止企业 / 申办者:European Organisation for Research and Treatment of Cancer - EORTC
药物 / 成分:Atezolizumab
登记的停止原因(原文):Following an urgent safety measure due to toxicity recruitment has been closed prematurely.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-22
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
编号:NCT03461952登记状态:提前终止企业 / 申办者:Canadian Cancer Trials Group
药物 / 成分:Nivolumab、Ipilimumab
登记的停止原因(原文):cfDNA screening data found that the prevalence of POLE/POLD1 mutations was lower than expected. It was determined that there are no feasible options to amend this study in a fashion that would not be duplicative of other currently accruing trials.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-22
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
编号:NCT03573544登记状态:提前终止企业 / 申办者:OBI Pharma, Inc
药物 / 成分:OBI-888、OBI-888、Globo H IHC Assay
登记的停止原因(原文):OBI-888 no longer fulfills our goal of developing cost-effective therapies for cancer patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-22
A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
编号:NCT04780464登记状态:提前终止企业 / 申办者:European Organisation for Research and Treatment of Cancer - EORTC
药物 / 成分:Doxorubicin、Doxorubicin、Cyclophosphamide Oral Product、Prednisolone
登记的停止原因(原文):Withdrawal grant provider
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-22
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
编号:NCT05387707登记状态:提前终止企业 / 申办者:Cara Therapeutics, Inc.
药物 / 成分:difelikefalin 0.25 mg、difelikefalin 0.5 mg、TCS Cream、Placebo
登记的停止原因(原文):In Part A of the study, oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone.
查看官方原始记录 ↗